Stock Track | Arrowhead Pharmaceuticals Soars 12.74% on Stellar Q2 Earnings, Beating Expectations

Stock Track

May 13

Arrowhead Pharmaceuticals (ARWR) stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.

The biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue for the quarter ended March 31, 2025, reached an impressive $543 million, dramatically outperforming analyst projections of $29.91 million.

During the earnings call, CEO Dr. Chris Anzalone highlighted the company's strong financial position and its readiness for its first commercial launch anticipated this year, pending regulatory approval for plozasiran. This financial performance marks a significant milestone for Arrowhead Pharmaceuticals as it transitions from a development-stage to a commercial-stage company. The combination of commercial expansion, a productive discovery engine, and a robust balance sheet positions Arrowhead Pharmaceuticals favorably for future growth, explaining the enthusiastic response from investors in today's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1195970269"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1195970269\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1195970269?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195970269","market":"nz","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 12.74% on Stellar Q2 Earnings, Beating Expectations","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (ARWR) stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.</p>\n\n<p>The biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue for the quarter ended March 31, 2025, reached an impressive $543 million, dramatically outperforming analyst projections of $29.91 million.</p>\n\n<p>During the earnings call, CEO Dr. Chris Anzalone highlighted the company's strong financial position and its readiness for its first commercial launch anticipated this year, pending regulatory approval for plozasiran. This financial performance marks a significant milestone for Arrowhead Pharmaceuticals as it transitions from a development-stage to a commercial-stage company. The combination of commercial expansion, a productive discovery engine, and a robust balance sheet positions Arrowhead Pharmaceuticals favorably for future growth, explaining the enthusiastic response from investors in today's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 12.74% on Stellar Q2 Earnings, Beating Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 12.74% on Stellar Q2 Earnings, Beating Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-13 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (ARWR) stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.</p>\n\n<p>The biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue for the quarter ended March 31, 2025, reached an impressive $543 million, dramatically outperforming analyst projections of $29.91 million.</p>\n\n<p>During the earnings call, CEO Dr. Chris Anzalone highlighted the company's strong financial position and its readiness for its first commercial launch anticipated this year, pending regulatory approval for plozasiran. This financial performance marks a significant milestone for Arrowhead Pharmaceuticals as it transitions from a development-stage to a commercial-stage company. The combination of commercial expansion, a productive discovery engine, and a robust balance sheet positions Arrowhead Pharmaceuticals favorably for future growth, explaining the enthusiastic response from investors in today's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1195970269","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195970269","pubTimestamp":1747143272,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals  stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.The biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"股票追踪Arrowhead Pharmaceuticals第二季度盈利出色，超出预期，股价飙升12.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.\nThe biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue for the quarter ended March 31, 2025, reached an impressive $543 million, dramatically outperforming analyst projections of $29.91 million.\nDuring the earnings call, CEO Dr. Chris Anzalone highlighted the company's strong financial position and its readiness for its first commercial launch anticipated this year, pending regulatory approval for plozasiran. This financial performance marks a significant milestone for Arrowhead Pharmaceuticals as it transitions from a development-stage to a commercial-stage company. The combination of commercial expansion, a productive discovery engine, and a robust balance sheet positions Arrowhead Pharmaceuticals favorably for future growth, explaining the enthusiastic response from investors in today's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}